Abstract
Acute activation of the sympathetic system and resultant β-adrenergic receptor (β-AR) signaling are required to maintain homeostasis, providing inotropic support in times of need, as in “fight or flight” or response to any stress, such as cardiac dysfunction and heart failure. For most of the twentieth century, it was reasoned that sympathetic stimulation of β-ARs through administration of naturally occurring catecholamines or synthetic sympathomimetic amines could provide inotropic support and should be used in heart failure therapy. However, in heart failure, sympathetic drive to the heart is excessively increased, and chronic sympathetic stimulation is deleterious, since it increases \( \text{M}\text{ {0.05em}}\stackrel{·}{\text{V}}\text{ {0.05em}}{\text{O}}_{2} \), which cannot be met by appropriate increases in coronary blood flow, thereby creating subendocardial ischemia and intensifying the cardiac dysfunction. Furthermore, continued stimulation of the β-ARs also becomes problematic because it can activate multiple cellular processes including those involved in pathological remodeling seen in the development of cardiomyopathy. However, this reasoning took a diametrically opposite turn in the latter twentieth century when the adverse effects of chronic β-AR stimulation became apparent from experimental studies in transgenic mice with cardiac-specific overexpression of Gsα and β-ARs and also from clinical studies with poor outcomes for patients on chronic sympathomimetic amine therapy. At this time it was also found that internal compensatory physiological processes countering continued β-AR stimulation in the heart were cleverer than physicians. As a protective response, β-AR desensitize, which reduces the effectiveness of β-AR stimulation and the consequent increases in myocardial oxygen demands. Taken together, these factors were fundamental to the change in course from β-AR stimulation to β-AR blockade in the treatment of heart failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cannon WB, Rosenbueth A (1933) Studies on conditions of activity in endocrine organs: XXIX. Sympathin E and sympathin I. Am J Physiol 104:557–574
Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586–600
Dale HH (1906) On some physiological actions of ergot. J Physiol 34:163–206
Dale H (1943) Modes of drug action. General introductory address. Trans Faraday Soc 39:319b–322b
De Jongh DK (1964) Some introductory remarks on the conception of receptors. In: Ariëns EJ (ed) Molecular pharmacology: the mode of action of biologically active compounds, vol 1. Academic, New York, NY, pp 13–15
Ahlquist RP (1967) Development of the concept of alpha and beta adrenotropic receptors. Ann N Y Acad Sci 139:549–552
Lands AM, Arnold A, McAuliff JP et al (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597–598
Carlsson E, Ablad B, Brandstrom A et al (1972) Differentiated blockage of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci 11:953–958
Alexander RW, Williams LT, Lefkowitz RJ (1975) Identification of cardiac beta-adrenergic receptors by (-)[3H]alprenolol binding. Proc Natl Acad Sci USA 72:1564–1568
Stiles GL, Taylor S, Lefkowitz RJ (1983) Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci 33:467–473
Kent RS, De Lean A, Lefkowitz RJ (1980) A quantitative analysis of beta adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14–23
Rodbell M (1980) The role of hormone receptors and GTP-regulating proteins in membrane transduction. Nature 284:17–22
Limbird LE, Gill DM, Lefkowitz RJ (1980) Agonist promoted coupling of the beta-adrenergic receptor with the guanine nucleotide regulatory protein of the adenylate cyclase system. Proc Natl Acad Sci USA 77:775–779
Dixon RA, Kobilka BK, Strader DJ et al (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79
Bylund DB (1992) Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J 6:832–839
Graham RM, Perez DM, Hwa J et al (1996) Alpha 1-adrenergic receptor subtypes. Molecular structure, function and signaling. Circ Res 78:737–749
Frielle T, Collins S, Daniel KW et al (1987) Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci USA 84:7920–7924
Emorine LJ, Marullo S, Delavier-Klutchko C et al (1987) Structure of the gene for human beta 2-adrenergic receptor: expression and promoter characterization. Proc Natl Acad Sci USA 84:6995–6999
Emorine LJ, Marullo S, Briend-Sutren MM et al (1989) Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118–1121
Lowell BB (1998) Using gene knockout and transgenic techniques to study the physiology and pharmacology of beta3-adrenergic receptors. Endocr J 45(Suppl):S9–S13
Rohrer DK, Desai KH, Jasper JR et al (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375–7380
Rohrer DK, Bernstein D, Chruscinski A et al (1998) The developmental and physiological consequences of disrupting genes encoding beta 1 and beta 2 adrenoceptors. Adv Pharmacol 42:499–501
Link RE, Stevens MS, Kulatunga M et al (1995) Targeted inactivation of the gene encoding the mouse alpha 2c-adrenoceptor homolog. Mol Pharmacol 48:48–55
Triposkiadis F, Karayannis G, Giamouzis G et al (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54:1747–1762
Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206–212
Port JD, Bristow MR (2001) beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol 60:629–631
Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93:896–906
Brodde OE, Bruck H, Leineweber K (2006) Cardiac adrenoceptors: physiological and pathological relevance. J Pharmacol Sci 100:323–337
Vatner SF, Franklin D, Higgins CB et al (1972) Left ventricular response to severe exertion in untethered dogs. J Clin Invest 51:3052–3060
Gauthier C, Tavernier G, Charpentier F et al (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98:556–562
Molinari C, Battaglia A, Grossini E et al (1999) The role of beta 2-adrenergic vascular receptors in the peripheral vasodilation caused by 17 beta-estradiol in anesthetized pigs. Life Sci 65:1545–1552
Arch JS, Ainsworth AT, Cawthorne MA et al (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163–165
Shen YT, Cervoni P, Claus T et al (1996) Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats, dogs. J Pharmacol Exp Ther 278:1435–1443
Tavernier G, Toumaniantz G, Erfanian M et al (2003) beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 59:288–296
Gauthier C, Leblais V, Kobzik L et al (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of the nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377–1384
Niu X, Watts VL, Cingolani OH et al (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59:1979–1987
Ishikawa Y, Homcy CJ (1997) The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 80:297–304
Gerhardstein BL, Puri TS, Chien AJ et al (1999) Identification of the sites phosphorylated by cyclic AMP-dependent protein kinase on the beta-2 subunit of the L-type voltage-dependent calcium channels. Biochemistry 38:10361–10370
Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365–376
Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78:921–947
Sulakhe PV, Vo XT (1995) Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Mol Cell Biochem 149–150:103–126
De Jongh KS, Murphy BJ, Colvin AA et al (1996) Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3′,5′-cyclic monophosphate-dependent protein kinase. Biochemistry 35:10392–10402
Ginsburg KS, Bers DM (2004) Modulation of excitation-contraction coupling by isoproterenol in cardiomyocytes with controlled SR Ca2+ load and Ca2+ current trigger. J Physiol 556:463–480
Shan J, Kushnir A, Betzenhauser MJ et al (2010) Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J Clin Invest 120:4388–4398
Luo W, Grupp IL, Harrer J et al (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75:401–409
MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4:566–577
Solaro RJ, Moir AJ, Perry SV (1976) Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 262:615–617
Zhang R, Zhao J, Mandveno A et al (1995) Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res 76:1028–1035
Kaumann A, Bartel S, Molenaar P (1999) Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99:65–72
Xiao RP, Ji X, Lakatta EG (1995) Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47:322–329
Xiao RP, Avdonin P, Zhou YY et al (1999) Coupling of beta2-adrenoreceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84:43–52
Lemoine H, Kaumann AJ (1991) Regional differences of beta1- and beta2-adrenoceptor-mediated functions in feline heart. A beta2-adrenoceptor mediated positive inotropic effects possibly unrelated to cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 334:56–69
McConville P, Fishbein KW, Lakatta EG et al (2003) Differences in the bioenergetic response of the isolated perfused rat heart to selective beta1- and beta2-adrenergic receptor stimulation. Circulation 107:2146–2152
McConville P, Spencer RG, Lakatta EG (2005) Temporal dynamics of inotropic, chronotropic and metabolic responses during beta1- and beta2-AR stimulation in the isolated, perfused rat heart. Am J Physiol Endocrinol Metab 289:E412–E418
Kilts JD, Gerhardt MA, Richardson MD et al (2000) Beta2-adrenergic and several other G protein-couple receptors in human atrial membranes activate both Gs and Gi. Circ Res 87:705–709
Molenaar P, Savarimuthu SM, Sarsero D et al (2007) (-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol 375:11–28
Bristow MR, Ginsburg R, Minobe W et al (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211
Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297–309
Kiuchi K, Shannon RP, Komamura K et al (1993) Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 91:907–914
Hittinger L, Mirsky I, Shen YT et al (1995) Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. Circulation 92:978–986
Nakano K, Corin WJ, Spann JF Jr et al (1989) Abnormal subendocardial blood flow in response to overload hypertrophy is associated with pacing-induced subendocardial dysfunction. Circ Res 65:1555–1564
Goldberg LI, Bloodwell RD, Braunwald E et al (1960) The direct effects of norepinephrine, epinephrine, and methoxamine on myocardial contractile force in man. Circulation 22:1125–1132
Smith HJ, Oriol A, Morch J et al (1967) Hemodynamic studies in cardiogenic shock. Treatment with isoproterenol and metaraminol. Circulation 35:1084–1091
Maroko PR, Kjekshus JK, Sobel BE et al (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67–82
Hittinger L, Shannon RP, Kohin S et al (1989) Isoproterenol-induced alterations in myocardial blood flow, systolic and diastolic function in conscious dogs with heart failure. Circulation 80:658–668
Lipp H, Fallicov RE, Resnekov L et al (1972) The effects of dopamine on depressed myocardial function following coronary embolization in the closed chest dog. Am Heart J 84:208–214
Gunnar RM, Loeb HS (1972) Use of drugs in cardiogenic shock due to acute myocardial infarction. Circulation 45:1111–1124
Tsai TH, Langer SZ, Trendelenburg U (1967) Effects of dopamine and alpha methyl-dopamine on smooth muscle and on the cardiac pacemaker. J Pharmacol Exp Ther 156:310–324
Nash CW, Wolff SA, Ferguson BA (1968) Release of tritiated noradrenaline from perfused rat hearts by sympathomimetic amines. Can J Physiol Pharmacol 46:35–42
Brodde OE, Inui J, Motomura S (1980) The mode of direct action of dopamine on the rabbit heart. J Cardiovasc Pharmacol 2:567–582
Chidsey CA, Braunwald E, Morrow AG et al (1963) Myocardial norepinephrine concentration in man: effects of reserpine and of congestive heart failure. N Engl J Med 269:653–658
Tuttle RR, Mills K (1975) Dobutamine. Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36:185–196
McNay JL, McDonald RH Jr, Goldberg LI (1965) Direct renal vasodilation produced by dopamine in the dog. Circ Res 16:510–517
Vatner SF, Millard RW, Higgins CB (1973) Coronary and myocardial effects of dopamine in the conscious dog: parasympatholytic augmentation of pressor and inotropic actions. J Pharmacol Exp Ther 187:280–295
Vatner SF, McRitchie RJ, Braunwald E (1974) Effects of dobutamine on left ventricular performance, coronary dynamics, and redistribution of cardiac output. J Clin Invest 53:1265–1273
Franciosa JA, Limas CJ, Guiha NH et al (1972) Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1:650–654
Guiha NJ, Cohn JN, Mikulic E et al (1974) Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 291:587–592
Miller RR, Vismara LA, Zelis R et al (1975) Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance. Circulation 51:328–336
Capomolla S, Febo O, Opasich C et al (2001) Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 3:601–610
Elkayam U, Tasissa G, Brinanay C et al (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153:98–104
Fitzpatrick D, Ikram H, Nicholls MG et al (1983) Hemodynamic, hormonal and electrolyte responses to prenalterol. Circulation 67:613–619
Petch MC, Wisbey C, Ormerod O et al (1984) Acute haemodynamic effects of oral prenalterol in severe heart failure. Br Heart J 52:49–52
Lambertz H, Meyer J, Erbel R (1984) Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 69:298–305
Gollub SB, Elkayam U, Young JB et al (1991) Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study. J Am Coll Cardiol 18:383–390
Asanoi H, Sasayama S, Sakurai T et al (1995) Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study. Cardiovasc Drugs Ther 9:791–797
Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997–1003
Installé E, Gonzales M, Jacquemart JL et al (1987) Comparative effects on hemodynamics of enoximone (MDL 17, 043), dobutamine and nitroprusside in severe congestive heart failure. Am J Cardiol 60:46C–52C
Cowley AJ, Skene AM (1994) Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone investigators. Br Heart J 72:226–230
Metra M, Eichhorn E, Abraham WT et al (2009) Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 30:3015–3026
Milano CA, Allen LF, Rockman HA et al (1994) Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264:582–586
Liggett SB, Tepe NM, Lorenz JN et al (2000) Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101:1707–1714
Tevaearai HT, Eckhart AD, Walton GB et al (2002) Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation 106:124–129
Iwase M, Bishop SP, Uechi M et al (1996) Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gs alpha overexpression. Circ Res 78:517–524
Asai K, Yang GP, Geng YJ et al (1999) Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest 104:551–558
Iwase M, Uechi M, Vatner DE et al (1997) Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 272:H585–H589
Engelhardt S, Hein L, Wiesmann F et al (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059–7064
Peter P, Brady J, Yan L et al (2007) Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest 117:1335–1343
Engelhardt S, Hein L, Dyachenkow V et al (2004) Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation 109:1154–1160
Du XJ, Gao XM, Wang B et al (2000) Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. Cardiovasc Res 48:448–454
Zaugg M, Xu W, Lucchinetti E et al (2000) Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation 102:344–350
Morisco C, Zebrowski DC, Vatner DE et al (2001) Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1) subtype in the rat heart. J Mol Cell Cardiol 33:561–573
Rona G, Chappel CI, Balazs T et al (1959) An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch Pathol 67:443–445
Rona G (1985) Catecholamine cardiotoxicity. J Mol Cell Cardiol 17:291–306
Chappel CI, Rona G, Balaz T et al (1959) Severe myocardial necrosis produced by isoproterenol in the rat. Arch Int Pharmacodyn Ther 112:123–128
Jalil JE, Janicki JS, Pick R et al (1989) Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res 65:258–264
Tisné-Versailles J, Constantin M, Lamar JC et al (1985) Cardiotoxicity of high doses of isoproterenol on cardiac haemodynamics and metabolism in SHR and WKY rats. Arch Int Pharmacodyn Ther 273:142–154
Kudej RK, Iwase M, Uechi M et al (1997) Effects of chronic beta-adrenergic receptor stimulation in mice. J Mol Cell Cardiol 29:2735–2746
Lai L, Yan L, Hu CL et al (2009) Abstract 3290: increased Type 5 adenylyl cyclase expression mediates chronic catecholamine stress via increases in oxidative stress and down-regulation of MnSOD. Circulation 120:S781
Balke CW, Shorofsky SR (1998) Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 37:290–299
Gwathmey JK, Morgan JP (1985) Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 57:836–843
Gwathmey JK, Copelas L, MacKinnon R et al (1987) Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61:70–76
Beuckelmann DJ, Näbauer M, Erdmann E (1992) Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046–1055
Bartel S, Stein B, Eschenhagen T et al (1996) Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem 157:171–179
Schröder F, Handrock R, Beuckelmann DJ et al (1998) Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation 98:969–976
Molkentin JD, Lu JR, Antos CL et al (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215–228
Zhang T, Johnson EN, Gu Y et al (2002) The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 227:1261–1267
Bloom S, Davis DL (1972) Calcium as mediator of isoproterenol-induced myocardial necrosis. Am J Pathol 69:459–470
Cheema Y, Sherrod JN, Zhao W et al (2011) Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J Cardiovasc Pharmacol 58:80–86
Yan L, Vatner DE, O’Connor JP et al (2007) Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2:247–258
Strohm C, Barancik T, Bruehl ML et al (2000) Inhibition of the ER-Kinase by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 36:218–229
Ping P, Zhang J, Cao X et al (1999) PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. Am J Physiol Heart Circ Physiol 276:H1468–H1481
Fryer RM, Hsu AK, Gross GJ (1995) ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection. Basic Res Cardiol 96:136–142
Yue TL, Gu JL, Wang C et al (2000) Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:37895–37901
Karoor V, Vatner SF, Takagi G et al (2004) Propranolol prevents enhanced stress signaling in Gs alpha cardiomyopathy: potential mechanism for beta-blockade in heart failure. J Mol Cell Cardiol 36:305–312
Condorelli G, Drusco A, Stassi G et al (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333–12338
Walsh K (2006) Akt signaling and growth of the heart. Circulation 113:2032–2034
DeBosch B, Treskov I, Lupu TS et al (2006) Akt1 is required for physiological cardiac growth. Circulation 113:2097–2104
Kim YK, Kim SJ, Yatani A et al (2003) Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem 278:47622–47628
Rota M, Boni A, Urbanek K (2005) Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ Res 97:1332–1341
Matsui T, Li L, del Monte F et al (1999) Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100:2373–2379
Fujio Y, Nguyen T, Wencker D et al (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660–667
Matsui T, Tao J, del Monte F et al (2001) Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104:330–335
Okumura S, Vatner DE, Kurotani R et al (2007) Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 116:1776–1783
Matsui T, Li L, Wu JC et al (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 227:22896–22901
Nagoshi T, Matsui T, Aoyama T et al (2005) PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 115:2128–2138
Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med 334:1349–1355
O’Connor CM, Gattis WA, Uretsky BF et al (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138:78–86
Ginsburg R, Bristow MR, Billingham ME et al (1983) Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 106:535–540
Fowler MB, Laser JA, Hopkins GL et al (1986) Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive down-regulation and subsensitivity to agonist response. Circulation 74:1290–1302
Bristow MR, Minobe WA, Raynolds MV et al (1993) Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 92:2737–2745
Ungerer M, Böhm M, Elce JS et al (1993) Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87:454–463
Pende A, Tremmel KD, DeMaria CT et al (1996) Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem 271:8493–8501
Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 4:2881–2889
Lohse MJ (1992) Mechanisms of b-adrenergic receptor desensitization. In: Hargrave PA, Hofmann KP, Kaupp UB (eds) Signal Transmission in Photoreceptor Systems. Berlin, Springer-Verlag, pp 160–171
Lohse MJ, Benovic JL, Caron MG et al (1990) Multiple pathways of rapid beta 2-adrenergic receptor desensitization. J Biol Chem 265:3202–3211
Benovic JL, Mayor F Jr, Staniszewski C (1987) Purification and characterization of the beta-adrenergic receptor kinase. J Biol Chem 262:9026–9032
Lohse MJ, Benovic JL, Codina J et al (1990) beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547–1550
Gerskowitch VP, Hull RAD, Shankley NP (1988) The pharmacological toolmakers rational approach to drug design—an appreciation of Sir James Black. Trends Pharmacol Sci 9:435–437
Black JW (1976) Ahlquist and the development of beta-adrenoceptor antagonists. Postgrad Med J 52(4):11–13
Black JW, Stephenson JS (1962) Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet 2:311–314
Elij D, Medez R (1964) The modification of digitalis intoxication by excluding adrenergic influences on the heart. J Pharmacol Exp Ther 144:97–103
Williams EM, Sekiya A (1963) Prevention of arrhythmias due to cardiac glycosides by block of sympathetic beta-receptors. Lancet 1:420–421
Somani P, Hardman HF, Lum BKB (1963) Antagonism of cardiac arrhythmias by nethalide. Phamacologist 5:260
Murray WJ, McKnight RL, Davis DA (1963) Antagonism of hydrocarbon anaesthetic-epinephrine arrhythmias in dogs by nethalide, a dichloroisoproterenol analogue. Proc Soc Exp Biol med 113:439–441
Prichard BN, Dickson CJ, Alleyne GA et al (1963) Effect of pronethalol in angina pectoris. Br Med J 2:1226–1229
Black JW, Duncan WA, Shanks RG (1965) Comparison of some properties of pronethalol and propranolol. Br J Phamacol Chemother 25:577–591
Allin EF, Miller JM, Rowe GG et al (1974) Effects of intraperitoneal administration of propranolol on the mouse heart. Histochemical and electron microscopic observations. Am J Cardiol 33:639–642
Fearson RE (1967) Propranolol in the prevention of ventricular fibrillation due to experimental coronary artery occlusion. Observation on its mode of action. Am J Cardiol 20:222–228
Khan MI, Hamilton JT, Manning GW (1972) Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs. Am J Cardiol 30:832–837
Mueller HS, Ayres SM, Religa A et al (1974) Propranolol in the treatment of acute myocardial infarction. Circulation 49:1078–1087
Hawkins CM, Richardson DW, Vokonas PS (1983) Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. Circulation 67:194–197
Hamer J, Grandjean T, Melendez L et al (1964) Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J 2:720–723
Keelan P (1965) Double-blind trial of propranolol (Inderal) in angina pectoris. Br Med J 1:897–898
Besterman EM, Friedlander DH (1965) Clinical experiences with propranolol. Postgrad Med J 41:526–535
Dunlop D, Shanks RG (1968) Selective blockade of adrenoceptive beta receptors in the heart. Brit J Pharmacol Chemother 32:201
Kubota T, Yamazaki N, Sudo J et al (1990) Protective effects of adrenoceptor-blocking agents on myocardial injury induced by epinephrine in mice. J Toxicol Sci 15:1–13
Waagstein F, Hjalmarson A, Varnauskas E et al (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022–1036
Waagstein F, Bristow MR, Swedberg K et al (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet 342:1441–1446
CIBIS investigators and committees (1994) A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765–1773
CIBIS-II investigators and committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353:9–13
Segev A, Mekori YA (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1361
Drummond GA, Squire IB (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1361
Poole-Wilson PA (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1360–1361
Hjalmarson A, Goldstein S, Fagerberg B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295–1302
Aarons RD, Molinoff PB (1982) Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J Pharmacol Exp Ther 221:439–443
Gilbert EM, Abraham WT, Olsen S et al (1996) Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94:2817–2825
Sigmund M, Jakob H, Becker H et al (1996) Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51:127–132
Bristow MR (2000) beta-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558–569
Hata JA, Williams ML, Koch WJ (2004) Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J Mol Cell Cardiol 37:11–21
Iaccarino G, Tomhave ED, Lefkowitz RJ et al (1998) Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98:1783–1789
Ping P, Gelzer-Bell R, Roth DA et al (1995) Reduced beta-adrenergic receptor activation decreases G-protein expression and beta-adrenergic receptor kinase activity in porcine heart. J Clin Invest 95:1271–1280
Leineweber K, Roche P, Beilfuss A et al (2005) G-Protein-coupled receptor kinase activity in human heart failure: effects of beta-adrenoceptor blockade. Cardiovasc Res 66:512–519
Brodde OE (2007) Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374:361–372
Bodor GS, Oakeley AE, Allen PD et al (1997) Troponin I phosphorylation in the normal and failing adult human heart. Circulation 96:1495–1500
Messer AE, Jacques AM, Marston SB (2007) Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 42:247–259
Reiken S, Wehrens XH, Vest JA et al (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459–2466
Lowes BD, Gilbert EM, Abraham WT et al (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357–1365
Abraham WT, Gilbert EM, Lowes BD et al (2002) Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 8:750–760
Frankenstein L, Nelles M, Slavutsky M et al (2007) Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 26:1033–1039
Iwatsubo K, Bravo C, Uechi M et al (2012) Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol 302:H2622–H2628
Shen TY, Malik FI, Zhao X et al (2010) Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 3:522–527
Malik FI, Hartman JJ, Elias KA et al (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331:1439–1443
Cleland JG, Teerlink JR, Senior R et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676–683
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lee, G.J.A., Yan, L., Vatner, D.E., Vatner, S.F. (2013). β-Adrenergic Receptor Signaling in Heart Failure. In: Jugdutt, B., Dhalla, N. (eds) Cardiac Remodeling. Advances in Biochemistry in Health and Disease, vol 5. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5930-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5930-9_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5929-3
Online ISBN: 978-1-4614-5930-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)